The FDA and safe use of long-acting beta-agonists in the treatment of asthma

N Engl J Med. 2010 Apr 1;362(13):1169-71. doi: 10.1056/NEJMp1002074. Epub 2010 Feb 24.

Authors

Badrul A Chowdhury¹, Gerald Dal Pan

Affiliation

¹ Division of Pulmonary and Allergy Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 20181964
DOI: 10.1056/NEJMp1002074

No abstract available

MeSH terms

Administration, Inhalation
Adrenal Cortex Hormones / therapeutic use
Adrenergic beta-Agonists / adverse effects*
Adrenergic beta-Agonists / therapeutic use
Asthma / drug therapy*
Asthma / mortality
Bronchodilator Agents / therapeutic use
Contraindications
Delayed-Action Preparations
Drug Approval*
Drug Labeling / legislation & jurisprudence
Drug Therapy, Combination
Humans
United States
United States Food and Drug Administration

Substances

Adrenal Cortex Hormones
Adrenergic beta-Agonists
Bronchodilator Agents
Delayed-Action Preparations